JAK1 and metastatic malignant neoplasm in the lymph nodes: In addition, the higher expression of JAK1 is associated with preferable OS in patients with N2 lymph node metastasis (HR: 0.39, 95% CI from 0.17 to 0.86, P = 0.016) without distant metastasis (HR: 0.73, 95% CI from 0.56 to 0.93, P = 0.013) of NSCLC.